IGF-1 LR3 Benefits: Claims vs What Studies Show
Benefits people claim for IGF-1 LR3, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human observational
- Human / animal studies
- 1 / 10
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- research chemical
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Bodybuilding | Human observational evidence, 3 of 4 | 1 / 0 | Black-market product composition; Regulatory status and evidence for physique claims | Evidence for bodybuilding |
| Muscle growth | Review only | 0 / 7 | Regulatory status and evidence for physique claims; Fetal growth; Body composition and cognition | Evidence for muscle growth |
| Growth hormone | Animal evidence, 2 of 4 | 0 / 2 | Insulin secretion; Growth performance; Endogenous GH | Evidence for growth hormone |
Strongest study per claim: Bodybuilding, Growth hormone & IGF research 2010, PMID 20675162; Muscle growth, Frontiers in endocrinology 2026, PMID 42395176; Growth hormone, Journal of developmental origins of health and disease 2023, PMID 37114757.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Black-market product composition | A black-market injection vial contained a His-tagged IGF-I variant; its effects in humans are not described. | Human case report | Growth hormone & IGF research 2010, PMID 20675162 |
| Regulatory status and evidence for physique claims | The review notes no regulatory approval for physique- or performance-related indications of these peptides, including the long-acting IGF analogue. | Review | Frontiers in endocrinology 2026, PMID 42395176 |
| Fetal growth | One week of IGF-1 LR3 did not improve growth in growth-restricted fetal sheep. | Animal · sheep (not a human result)n = 14 | American journal of physiology. Endocrinology and metabolism 2025, PMID 39679943 |
| Body composition and cognition | Intranasal LR3-IGF-1 improved body composition (not specified in the abstract) in male 5XFAD mice but did not significantly change cognition. | Animal · mouse (not a human result) | Journal of Alzheimer's disease 2025, PMID 39610283 |
| Insulin secretion | Fetal plasma insulin fell with infusion, and insulin during the hyperglycemic clamp was 66% lower than control. | Animal · sheep (not a human result)n = 10 | Journal of developmental origins of health and disease 2023, PMID 37114757 |
| Daily weight gain | In the second 9 days, LR3IGF-I-infused neonatal pigs gained 457 g/d versus 386 g/d for controls. | Animal · pig (not a human result) | The British journal of nutrition 2002, PMID 12067429 |
| Clearance from wound fluid | Half-life in wound fluid was 563 min for LR3-IGF-I versus 872 min for IGF-I, 861 for IGF-II and 324 for insulin. | Animal · rat (not a human result) | The American journal of physiology 1999, PMID 10198302 |
| Growth performance | A four-day infusion of 180 micrograms/kg/day LR3IGF-I decreased average daily gain, food intake and plasma IGFBP-3, IGF-I and insulin in pigs. | Animal · pig (not a human result) | The Journal of endocrinology 1997, PMID 9488001 |
| Endogenous GH | Mean plasma GH fell by 23% and the area under the GH peaks by 60%. | Animal · pig (not a human result) | The Journal of endocrinology 1997, PMID 9488001 |
| Overall growth | Fractional weights of adrenals, gut, kidneys and spleen increased with LR3IGF-I, but overall growth was not stimulated. | Animal · guinea pig (not a human result) | The Journal of endocrinology 1995, PMID 7561636 |
| Body and gut weight | LR3IGF-I (not IGF-I) increased body weight and wet weight of small and large intestine by 20% versus controls; muscle was not measured. | Animal · rat (not a human result) | Gut 1995, PMID 8549937 |
| Carcass protein | LR3-IGF-I had no positive effect on carcass protein accretion in tumour-bearing rats. | Animal · rat (not a human result) | The Biochemical journal 1994, PMID 8053901 |
| Growth in diabetic rats | The IGF-I variants were 2.5-3 times more potent than IGF-I at restoring growth in diabetic rats. | Animal · rat (not a human result) | The Biochemical journal 1993, PMID 7683875 |
| Muscle protein synthesis | All IGF peptides raised muscle protein-synthesis rates and RNA levels by up to 50%, IGF-I least. | Animal · rat (not a human result) | The Biochemical journal 1993, PMID 7683875 |
Claim: it builds muscle
In streptozotocin-diabetic rats infused by pump, LR3-IGF-I and a truncated variant were 2.5 to 3 times more potent than IGF-I in restoring growth; this is rat data.[12]
In those diabetic rats all the peptides raised muscle protein-synthesis rates and RNA levels by up to 50%, IGF-I least of all.[12]
In rats carrying a mammary tumour, LR3-IGF-I had no positive effect on carcass protein and tumour growth rose, especially with LR3-IGF-I.[11]
In growing finisher pigs, a short LR3IGF-I infusion lowered daily gain and food intake rather than raising them.[8]
Claim: it raises growth hormone and IGF levels
In finisher pigs both IGF-I and LR3IGF-I suppressed plasma growth hormone, the opposite of a rise.[8]
In guinea pigs, LR3IGF-I raised the fractional weight of the adrenals, gut, kidneys and spleen, but overall growth was not stimulated.[9]
In artificially-reared neonatal pigs, LR3IGF-I increased daily weight gain in the second 9 days of one experiment (457 versus 386 g a day).[6]
Claim: it heals and protects other tissues
In rats, LR3IGF-I, but not IGF-I, increased body weight and the wet weight of the small and large intestine by 20%.[10]
In male 5XFAD Alzheimer's mice given intranasal LR3-IGF-1, body composition improved but cognition did not.[4]
In growth-restricted fetal sheep, a 1-week LR3 treatment did not improve growth.[3]
Claims with no human study behind them
A PubMed search of IGF-1 LR3 with muscle-mass and muscle-growth terms (2026-10-02) found 0 human-only papers and 6 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND ("muscle mass"[tiab] OR "lean mass"[tiab] OR "lean body mass"[tiab] OR "fat-free mass"[tiab] OR "muscle growth"[tiab] OR "muscle hypertrophy"[tiab] OR "muscle protein synthesis"[tiab] OR "muscle strength"[tiab] OR sarcopeni*[tiab] OR "muscle wasting"[tiab] OR "muscle atrophy"[tiab]); date 2026-10-02; human only count 0; animal filter count 6; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
A PubMed search of IGF-1 LR3 with bodybuilding and resistance-training terms (2026-10-02) found 0 human-only papers and 4 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (bodybuild*[tiab] OR "resistance training"[tiab] OR "resistance exercise"[tiab] OR "strength training"[tiab] OR "weight training"[tiab] OR weightlift*[tiab] OR "muscle hypertrophy"[tiab] OR "muscle mass"[tiab] OR "lean mass"[tiab] OR "anabolic steroid"[tiab] OR "anabolic steroids"[tiab] OR "anabolic-androgenic"[tiab]); date 2026-10-02; human only count 0; animal filter count 4; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
A narrative review of performance-enhancing peptides notes the absence of regulatory approval for physique- or performance-related indications, so the muscle and bodybuilding claims above rest on animal work and on forum use.
Calculated from source PMID 42395176 abstract; human trials found 0. Formula: summary of the review abstract and the two ledger counts
More on IGF-1 LR3
Common questions
Is IGF-1 LR3 proven to work?
The strongest study we summarise for IGF-1 LR3 is human observational evidence, among 12 studies. That is not proof it works in people.
What does IGF-1 LR3 do?
In animal studies, IGF-1 LR3 is a long-arginine IGF-1 analogue with low affinity for IGF-binding proteins and high affinity for the IGF-1 receptor.[3]
Are there benefits of IGF-1 LR3 in people?
The cached abstracts are all animal or cell studies, and a narrative review lists IGF-1 LR3 among unapproved performance-enhancing peptides.[2]
More on IGF-1 LR3
Sources
- 1Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 2The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 3IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
- 4Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
- 5Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.Journal of developmental origins of health and disease · 2023PMID 37114757Accessed 2 Oct 2026
- 6Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
- 7Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 8Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
- 9Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.The Journal of endocrinology · 1995PMID 7561636Accessed 2 Oct 2026
- 10Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats.Gut · 1995PMID 8549937Accessed 2 Oct 2026
- 11Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.The Biochemical journal · 1994PMID 8053901Accessed 2 Oct 2026
- 12Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 13PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) (109 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("Long R3 IGF-I"[tiab] OR "LR3 IGF-I"[tiab] OR "IGF-I LR3"[tiab] OR "LR3-IGF-I"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab] OR "[Long R3]IGF-I"[tiab]) AND (rat[tiab] OR rats[tiab] OR mice[tiab] OR infusion[tiab] OR muscle[tiab] OR pigs[tiab] OR in vivo[tiab]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: "long R3 IGF"[tiab] OR "long-R3 IGF"[tiab] OR "LR3-IGF"[tiab] OR "LR3 IGF"[tiab] OR "R3 IGF-I"[tiab] (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("LR3"[tiab] AND IGF[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR clearance[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("Long R3"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF"[tiab] OR "LR3-IGF"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.